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Background. Patterns of morbidity and mortality among human immunodeficiency virus (HIV)–infected
individuals taking antiretroviral therapy are changing as a result of immune reconstitution and improved survival.
We studied the influence of aging on the epidemiology of non-AIDS diseases in the Swiss HIV Cohort Study.
Methods. The Swiss HIV Cohort Study is a prospective observational cohort established in 1988 with
continuous enrollment. We determined the incidence of clinical events (per 1000 person-years) from January 2008
(when a new questionnaire on non–AIDS-related morbidity was introduced) through December 2010. Differences
across age groups were analyzed using Cox regression, adjusted for CD4 cell count, viral load, sex, injection drug
use, smoking, and years of HIV infection.
Results. Overall, 8444 (96%) of 8848 participants contributed data from 40 720 semiannual visits; 2233 individuals
(26.4%) were aged 50–64 years, and 450 (5.3%) were aged$65 years. The median duration of HIV infection was 15.4
years (95% confidence interval [CI], 9.59–22.0 years); 23.2% had prior clinical AIDS. We observed 994 incident non-
AIDS events in the reference period: 201 cases of bacterial pneumonia, 55 myocardial infarctions, 39 strokes, 70 cases
of diabetes mellitus, 123 trauma-associated fractures, 37 fractures without adequate trauma, and 115 non-AIDS
malignancies. Multivariable hazard ratios for stroke (17.7; CI, 7.06–44.5), myocardial infarction (5.89; 95% CI, 2.17–
16.0), diabetes mellitus (3.75; 95% CI, 1.80–7.85), bone fractures without adequate trauma (10.5; 95% CI, 3.58–30.5),
osteoporosis (9.13; 95% CI, 4.10–20.3), and non–AIDS-defining malignancies (6.88; 95% CI, 3.89–12.2) were elevated
for persons aged $65 years.
Conclusions. Comorbidity and multimorbidity because of non-AIDS diseases, particularly diabetes mellitus,
cardiovascular disease, non–AIDS-defining malignancies, and osteoporosis, become more important in care of
HIV-infected persons and increase with older age.
Antiretroviral therapy (ART) has improved quality of
life and increased life expectancy among human im-
munodeficiency virus (HIV)–infected individuals.
Consequently, patterns of mortality [1] and morbidity
[2] are changing among the human immunodefi-
ciency virus (HIV)–infected population. The focus of
care has shifted away from immunodeficiency-related
opportunistic infections or AIDS-defining malignan-
cies to ART-related problems (including toxicities,
drug-drug interactions, or antiretroviral drug re-
sistance) and, more recently, to various non-AIDS
diseases [3–5]. Such comorbidites, often occurring
sequentially or concurrently, may be the consequence of
long-term ART toxicities, a state of chronic in-
flammation because of HIV infection [6], lifestyle-
related risks for disease, and aging [7]. Many studies
assessing the occurrence of comorbid conditions in
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HIV-infected persons have had a disease-specific focus, com-
paring the prevalence or incidence of a single clinical event
among HIV-infected patients with that among demographically
similar HIV-uninfected individuals [8–12], but only a few
studies have aimed to investigate the extent and consequences of
multimorbidity in the HIV-infected population.
In the Swiss HIV Cohort Study (SHCS), the proportion of
older participants has increased in recent years (Figure 1). We
aimed to study the influence of aging on the epidemiology of
non-AIDS diseases in our cohort. We calculated incidences and
hazard ratios for different clinical events and compared partic-
ipants in different age groups (,50, 50–64, and $65 years of
age). Because of the prospective and in-depth design of the co-
hort, we were able to adjust for many factors known to be
associated with HIV disease progression or risk factors associ-
ated with non-AIDS comorbidity.
METHODS
Study Design and Data Collection
The SHCS is a prospective observational cohort study with con-
tinued enrollment of HIV-infected persons aged $16 years who
attend outpatient clinics at 7 cohort centers, affiliated regional
hospitals, or private practitioners collaborating with the centers.
Standardized data collection forms containing demographic,
psychosocial, clinical, laboratory, and treatment information are
completed every 6months by physicians and study nurses [13, 14].
HIV-associated opportunistic infections and malignancies
have been documented since 1988, and immune reconstitution
inflammatory syndrome has been reported since 2005. The
SHCS is participating in the Data Collection on Adverse Events
of Anti-HIV Drugs (D:A:D) cohort, which has collected detailed
information on cardiovascular end points and diabetes mel-
litus since 1999; end points are centrally reviewed and vali-
dated [15]. In 2008, the D:A:D cohort introduced additional
end point forms and adjudication procedures for renal disease,
liver disease, and non-AIDS malignancies. In addition, in 2008,
the SHCS started to collect information on bone-related events,
bacterial pneumonia, and pancreatitis. Detailed information on
alcohol consumption has been collected in the SHCS since
August 2005; detailed data on injection and noninjection drug
consumption have been reported since April 2007.
Study Participants
SHCS participants with at least 1 cohort visit from 1 January
2008 through 31 December 2010 were included in the analyses.
Participants were categorized into 3 age groups: ,50, 50–64,
and$65 years of age. We limited the analysis to the 3 main HIV
transmission categories: men who have sex with men, hetero-
sexual individuals, and injection drug users. The protocol of the
SHCS was approved by local ethical committees, and written
informed consent was obtained from all participants.
Definitions
Body mass index was calculated as weight in kilograms divided
by the square of height in meters. Hypertension was diagnosed
in participants with a diastolic or a systolic blood pressure$90/
$160 mm Hg or in those who took antihypertensive medi-
cations. If participants reported physical changes in face, arms,
legs, abdomen, buttocks, breasts, or neck and if this physical
change was confirmed during examination, the patient was as-
signed to have lipoatrophy or lipoaccumulation, depending on
the situation. As a correlate of kidney function, estimates of the
glomerular filtration rate were calculated using the Modification
of Diet in Renal Disease equation [16]. Active hepatitis B virus
(HBV) infection was defined as positive HBV surface antigen or
HBV e antigen or HBV DNA. Hepatitis C virus (HCV) infection
was defined as positive HCV antibody and positive HCV RNA.
Alcohol use was stratified according to the World Health
Organization definition into severe (for female patients,.40 g/d;
for male patients, .60 g/d), moderate (for female patients,
20–40 g/d; for male patients, 40–60 g/d), and light use (for
female patients, ,20 g/d; for male patients, ,40 g/d). The
term ‘‘clinical AIDS’’ was used if an individual had a previous
AIDS-defining infection or malignancy.
To assess the effects of viral load on clinical events, we cap-
tured the ART status at the last cohort visit before a new event or
at the patient’s last cohort visit, whichever was applicable. In-
formation on ART included age at start of therapy, era of starting
ART (mono/dual versus combination ART), ART status (ART-
naive, currently not receiving ART, receiving ART with HIV
RNA level ,50 copies/mL, receiving ART with HIV RNA
$50 copies/mL), adherence to ART during the 4 weeks before the
last cohort visit, years of cumulative exposure to ART, current
drug regimens (ART combinations based on protease inhibitor
[PI], nonnucleoside reverse-transcriptase inhibitor [NNRTI],
NNRTI and PI, or nucleoside reverse-transcriptase inhibitor
[NRTI]), and individual drugs. The term ‘‘mono/dual’’ was used
in case of ART initiation with 1 or 2 antiretroviral drugs, and the
term ‘‘combination ART’’ was used for $3 drug combinations.
Figure 1. Age distribution among active participants of the Swiss HIV
Cohort Study over time.
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Statistical Analysis
Trends across age groups for different characteristics and con-
ditions were analyzed using nonparametric tests for trend. In-
cidences of clinical events were calculated as the number of new
events divided by the number of person-years of follow-up.
Follow-up was counted from the first visit after 1 January 2008
to the date of the first diagnosis of new clinical events or the
patient’s last cohort visit, whichever occurred first.
Associations with age were analyzed in uni- and multivariable
Cox proportional hazards regression models. Multivariable
models were adjusted for latest square-root–transformed CD4
cell counts, latest log10-transformed HIV RNA level, female sex,
former and current injection drug use, former and current
smoking, and duration of HIV infection. Duration of HIV in-
fection was calculated as years since seroconversion with use of
imputed dates of seroconversion [17]. Eight percent of clinical
observations (in particular, liver-associated events and bacterial
pneumonias) had to be deleted because of missing covariables.
Competing risk-of-death analyses, according to the method of
Fine and Gray [18], were performed for the different clinical
outcomes.
We used Stata, version 11.1 (StataCorp), for analyses.
RESULTS
From 1 January 2008 through 31 December 2010, 8844 partic-
ipants contributed to 40,720 cohort visits and 22 591 person-years
of follow-up. Four hundred four participants were excluded be-
cause they either had HIV-2 infection (n5 11) or did not belong
to the main HIV transmission groups (perinatal, 46; blood, 77;
other, 60; and unknown transmission, 210 participants).
Baseline Characteristics of Participants
Demographic and clinical characteristics of participants, strati-
fied by age groups, are shown in Table 1. The median age of our
cohort was 45 years (interquartile range [IQR], 39–51 years). Of
8444 individuals, 5761 (68%) were,50 years of age, 2233 (26%)
were 50–64 years of age, and 450 (5%) were $65 years of age.
Overall, 2464 (29%) were female, and 1963 (23%) had prior
clinical AIDS. The nadir CD4 cell count was 190 cells/lL
(IQR, 84–288 cells/lL), and the latest CD4 cell count was
528 cells/lL (IQR, 377–711 cells/lL).
In persons aged .65 years and those aged 50–64 years, the
median duration of HIV infection was 15.7 years (IQR, 11.8–21.5
years) and 18.2 years (IQR, 12.8–23.5 years), respectively. Older
persons aged.65 years were less likely to belong to the injection
drug use HIV transmission group (0.7% in the .65 years age
group vs 17.4% in the 50–64 years age group), were less likely to
be HCV infected (6.2% vs 24.9%) and were less likely to be
current smokers (16.9% vs 41.2%). Test-for-trend analyses
across age groups showed associations with virtually all baseline
conditions. The probability of prior clinical AIDS, cardiovas-
cular risk factors, diabetes mellitus, or lipodystrophy was in-
creasing with age, and renal function was decreasing with age.
Antiretroviral Therapy Status and Non-HIV Comedication
A total of 7184 (85%) of 8444 participants were taking ART, and
5834 (81%) of the 7184 participants had an undetectable viral
load at the last cohort visit in the reference period or just before
the clinical event (Table 2). The median age at start of ART was
36 years (IQR, 31–43 years), and the median duration of treat-
ment was 6.4 years (IQR, 0.929–11.7 years). One-third of par-
ticipants were receiving a PI-based regimen, and one-third were
receiving an NNRTI-based regimen. Older patients were more
frequently taking ART, had more frequently suppressed viral
replication, and were more frequently taking non-HIV come-
dications. Of 8444 participants, 2591 (31%) received at least
1 non-HIV comedication. Figure 2A shows the percentage of
participants with their respective numbers of non-HIV medi-
cation, stratified by age. One hundred fifteen (5.2%) of 2233
participants aged 50–64 years and 64 (14.2%) of 450 partic-
ipants aged .65 years received $4 comedications.
Incidence of Clinical Events
Numbers of non-AIDS comorbidities, HIV-related complica-
tions, hospitalizations, and deaths, stratified by age, are shown in
Table 3. One hundred seventy-seven (2.10%) of 8444 persons
died. The leading causes of death were malignancies (40 [23%]
of 177), infectious diseases (14.6%), and cardiovascular events
(12.4%).
Of the 8444 participants, 1812 (21.5%) were hospitalized
during the reference period. Somatic reasons (79.9%), psychiatric
reasons (13.5%), and injuries (6.6%) accounted for most hospi-
talizations. Of 8444 cohort participants, 95 developed a new
AIDS-defining illness and 100 developed a Centers for Disease
Control and Prevention (CDC) stage B disease. We observed
994 incident non-AIDS clinical events during the reference
period. Among the 115 non-AIDS malignancies, malignant
neoplasm of the liver was the most frequent (16 [12.7%] of
115), followed by neoplasms of the lung (10.3%), prostate
(7.14%), breast (5.56%), and skin (5.56%). Numbers of dif-
ferent non-AIDS comorbidities, stratified by age, are provided
in Figure 2B. One hundred one (4.5%) of 2233 participants
aged 50–64 years and 23 (5.3%) of 450 participants aged
.65 years had $4 comorbidities.
The incidence rate (IR) of death was 7.81 deaths per 1000
person-years (95% confidence interval [CI], 6.74–9.05 deaths per
1000 person-years), of any hospitalization was 87.5 hospital-
izations per 1000 person-years (95%CI, 83.5–91.7 hospitalizations
per 1000 person-years), of clinical AIDS was 4.32 cases per 1000
person-years (95%CI, 3.53–5.28 cases per 1000 person-years), and
of any clinical event was 53.3 cases per 1000 person-years (95%CI,
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50.3–56.6 cases per 1000 person-years). IRs for selected non-
AIDS events, IRs per age stratum, and results of test-for-trend
analyses are summarized in Table 3. Incidences for death and
hospitalization were elevated in older participants, compared
with those aged ,50 years. Also, IRs for bacterial pneumonia,
stroke, coronary angioplasty, myocardial infarction, proce-
dures on other arteries, bone fracture with assumed adequate
or inadequate trauma, osteoporosis, new diabetes event,
pancreatitis, and non-AIDS malignancy were higher for older
participants (all P , .05).
Age-Associated Risks for Non-AIDS Events
Uni- and multivariable hazard ratios (HRs) for death, hospi-
talizations, HIV-associated, and non-AIDS events are shown
Table 1. Clinical Baseline Characteristics of 8444 HIV-Seropositive Cohort Participants, Stratified by Age
Age group
Variable Total ,50 years 50–64 years $65 years P valuea
Patients, no. (%) 8444 (100) 5761 (68.2) 2233 (26.4) 450 (5.3)
Female, no. (%) 2464 (29.2) 1932 (33.5) 453 (20.3) 79 (17.6) ,.001
HIV transmission groups, no. (%) .322
MSM 3627 (42.9) 2401 (41.6) 1017 (45.5) 209 (46.4)
Heterosexual 3393 (40.2) 2328 (40.4) 827 (37.0) 238 (52.9)
IDU 1424 (16.8) 1032 (17.9) 389 (17.4) 3 (0.70)
Prior clinical AIDS, no. (%) 1963 (23.2) 1160 (20.1) 660 (29.5) 143 (31.8) ,.001
Age at HIV diagnosis, median years (IQR) 29 (23–36) 26 (21–31) 37 (30–43) 54 (48–60) ,.001
Years HIV-infected, median (IQR) 15.4 (9.59–22.0) 14.0 (8.58–21.1) 18.2 (12.8–23.5) 15.7 (11.8–21.5) ,.001
First CD4 cells/lL, median (IQR) 350 (180–542) 367 (200–554) 310 (147–527) 285 (127–480) ,.001
Nadir CD4 cells/lL, median (IQR) 190 (84–288) 206 (102–306) 149 (62–245) 161 (67–254) ,.001
Years CD4 ,200 cells/lL, median (IQR) 0.916 (0–12.5) 0 (0–10.1) 3.19 (0–18.3) 1.98 (0–14.5) ,.001
CD4 cells/lL at last visit, median (IQR) 528 (377–711) 532 (383–717) 523 (370–710) 471 (329–627) ,.001
BMI, kg/mb, median (IQR) 23.5 (21.2–26.1) 23.3 (21.1–25.9) 23.8 (21.3–26.5) 24.2 (22.1–26.7) ,.001
Smoking, no. (%) ,.001
Never 2688 (31.8) 1828 (31.7) 657 (29.4) 203 (45.1)
Ever 2009 (23.8) 1185 (20.6) 654 (29.3) 170 (37.8)
Current 3735 (44.2) 2740 (47.5) 919 (41.2) 76 (16.9)
Hypertension, no. (%)b 4753 (56.3) 2839 (49.3) 1559 (69.8) 355 (78.9) ,.001
Diabetes mellitus, no. (%) 350 (4.1) 121 (2.1) 156 (7.0) 73 (16.2) ,.001
Fat loss, no. (%)c 1425 (16.9) 682 (11.8) 611 (27.4) 132 (29.3) ,.001
Fat accumulation, no. (%)d 1514 (17.9) 822 (14.3) 568 (25.4) 124 (27.6) ,.001
Hepatitis B virus coinfection, no. (%) 339 (4.0) 255 (4.4) 67 (3.0) 17 (3.8) ,.001
Hepatitis C virus coinfection, no. (%) 1915 (22.7) 1332 (23.1) 555 (24.9) 28 (6.2) ,.001
Depression, no. (%) 1282 (15.2) 852 (14.8) 382 (17.1) 48 (10.7) .911
MDRD, mL/min, median (IQR) 101 (86.5–111) 106 (92.4–115) 93.8 (79.5–102) 75.2 (62.1–87.0) ,.001
Drug use, no. (%)
Illicit injectables in the past 6 months 217 (2.6) 176 (3.1) 41 (1.8) 0 (0) ,.001
Illicit noninjectables in the past 6 months 1522 (18.0) 1202 (20.8) 315 (14.1) 5 (1.1) ,.001
Opiate substitution treatment program 771 (9.1) 576 (10.0) 195 (8.7) 0 (0) ,.001
Alcohol use, no. (%)e .001
Moderate 411 (4.9) 261 (4.5) 120 (5.4) 30 (6.7)
Severe 217 (2.6) 151 (2.6) 56 (2.5) 10 (2.2)
Abbreviations: HIV, human immunodeficiency virus; MSM, men who have sex with men; IDU, injecting drug users; BMI, body mass index; IQR, interquartile range;
MDRD, modification of diet in renal disease; CHD, coronary heart disease.
a Test for trend across age-groups.
b Definition of hypertension: $160/$90 mm Hg.
c Fat loss in any of the following regions: face, arms, legs, buttocks, breasts, neck. Presence of a least one patient-reported physical change confirmed on physical
examination, irrespective of antiretroviral therapy or it’s composition.
d Fat accumulation in any of the following regions: Face, arms, legs, buttocks, abdomen, breasts, and neck. Presence of a least one patient-reported physical
change confirmed on physical examination, irrespective of antiretroviral therapy or it’s composition.
e Alcohol consumption categorized according to the WHO criteria: moderate (20-40 g for women and 40-60 g for men) or severe health risk (.40 g per day for
women and .60 g for men).
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in Table 4. In participants aged 50–64 years and $65 years,
univariable HR for death and the following comorbidities were
elevated, compared with younger persons: bacterial pneumonia,
stroke, coronary angioplasty, myocardial infarction, procedure
on other arteries, bone fractures with assumed adequate or in-
adequate trauma, osteoporosis, diabetes mellitus, pancreatitis,
and non–AIDS-defining malignancies (all P , .05). After mul-
tivariable adjustment, associations with age remained unchanged
for these end points. The global P value for age, obtained
through a comparison of the likelihoods between models that
did not include age, was P , .001 for most clinical events,
suggesting that the overall effect of age on clinical events was
strong.
Strong associations (P , .001) of covariables with the dif-
ferent end points were found in the respective multivariable
models. Square-root CD4 cell counts were inversely associated
with the development of bacterial pneumonias (HR, 0.939;
95% CI, 0.916–0.961), bone fractures without adequate trauma
Table 2. Treatment Characteristics of 8444 HIV-Seropositive Cohort Participants, Stratified by Age
Age group
Variables Total ,50 years 50–64 years $65 years P valuea
ART
Age at ART start, years, median (IQR) 36 (31–43) 33 (29–37) 44 (39–49) 60 (55–64) ,.001
Era of starting ART, no. (%) ,.001
Mono/Dual 2212 (26.2) 1210 (21.0) 850 (38.1) 152 (33.8)
Combination ART 5681 (67.3) 4084 (70.9) 1309 (58.6) 288 (64.0)
Status at last visit, no. (%) ,.001
ART-naive 551 (6.5) 467 (8.1) 74 (3.4) 10 (2.2)
ART interrupted 709 (8.4) 544 (9.4) 137 (6.1) 28 (6.2)
On ART, VL ,50 copies/mL 5834 (69.1) 3808 (66.1) 1685 (75.5) 341 (75.8)
On ART, VL .50 copies/mL 1350 (16.0) 942 (16.4) 337 (15.1) 71 (15.8)
Regimens at last visit, no. (%) ,.001
PI-based 2888 (34.2) 2042 (35.4) 710 (31.7) 136 (30.12)
NNRTI-based 2765 (32.8) 1813 (31.5) 782 (35.0) 170 (37.8)
PI 1 NNRTI–based 472 (5.6) 244 (4.2) 194 (8.7) 34 (7.6)
NRTI only 356 (4.2) 225 (3.9) 100 (4.5) 31 (6.9)
Other ART 703 (8.3) 426 (7.4) 236 (10.6) 41 (9.1)
Use of new drugs at last visit, no. (%)
Etravirine 417 (4.9) 257 (4.5) 140 (6.3) 20 (4.4) .029
Enfurvitide 9 (0.1) 4 (0.07) 4 (0.2) 1 (0.2) .128
Raltegravir 572 (6.8) 308 (5.3) 230 (10.3) 34 (7.6) ,.001
Maraviroc 54 (0.6) 29 (0.5) 20 (0.9) 5 (1.1) .020
Darunavir/Ritonavir 688 (8.1) 456 (7.9) 198 (8.9) 34 (7.6) .464
Adherence to ART during last 4 weeks, no. (%) .021
Never missed a dose 5753 (83.8) 3762 (83.3) 1634 (84.2) 357 (88.2)
1 missed dose/month 755 (11.0) 514 (11.4) 209 (10.8) 32 (7.9)
.1 missed dose/month 354 (5.2) 241 (5.3) 97 (5.0) 16 (4.0)
Time on ART, median (IQR)
Overall years 6.40 (0.929–11.7) 4.70 (0–10.1) 9.84 (4.25–13.6) 9.84 (5.08–13.6) ,.001
Years on mono/dual 1.50 (0.498–3.74) 1.17 (0.288–3.25) 2.00 (0.748–4.15) 1.87 (0.711–4.20) ,.001
Non-ART medication, no. (%)
Antihypertensives (not ACE inhibitors) 831 (9.8) 323 (5.6) 367 (16.4) 141 (31.3) ,.001
Antihypertensives (ACE inhibitors) 935 (11.1) 355 (6.2) 432 (19.4) 148 (32.9) ,.001
Lipid-lowering agents 1071 (12.7) 356 (6.2) 527 (23.6) 188 (41.8) ,.001
Oral antidiabetics 179 (2.1) 51 (0.9) 87 (3.9) 41 (9.1) ,.001
Insulin 116 (1.4) 40 (0.7) 50 (2.2) 26 (5.8) ,.001
Antiplatelet drugs 488 (5.8) 121 (2.1) 237 (10.6) 130 (28.9) ,.001
Antidepressants 846 (10.0) 560 (9.7) 251 (11.2) 35 (7.8) .659
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; VL, viral load; PI, Protease inhibitor, NNRTI, Non-nucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor; ACE, Angiotensin-converting enzyme.
a Test for trend across age groups.
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(HR, 0.897; 95% CI, 0.847–0.950), osteoporosis (HR, 0.906; 95%
CI, 0.866–0.947), new AIDS-defining events (HR, 0.908; 95%
CI, /INS> 0.877–0.941), and death (HR, 0.880; 95% CI, 0.858–
0.903). Log10–transformed viral load was associated with HIV-
associated events (CDC B defining event: HR, 1.64 [95% CI,
1.48–1.82]; CDC C event: HR, 1.51 [95%CI, 1.37–1.68]). Female
sex was positively associated with osteoporosis (HR, 2.98;
95% CI, 1.77–5.03). Former injection drug use was associated
with bacterial pneumonia (HR, 2.68; 95% CI, 1.90–3.78), liver-
associated events (HR, 5.71; 95%CI, 2.99–10.87), and death (HR,
2.78; 95% CI, 1.93–4.02); current injection drug use was associ-
ated with bacterial pneumonia (HR, 3.15; 95% CI, 1.81–5.49)
and liver-associated events (HR, 5.81; 95% CI, 2.02–16.7).
Former smoking was associated with death (HR, 2.78; 95% CI,
1.93–4.02); current smoking was associated with bacterial
pneumonia (HR, 2.17; 95% CI, 1.42–3.33) and death (HR, 2.40;
95% CI, 1.53–3.76). Duration of HIV infection was inversely
associated with the development of CDC B events (HR, 0.957;
95% CI, 0.936–0.978).
Sensitivity Analyses
We performed competing risk-of-death analyses with the as-
sumption that different end points might be underestimated in
older HIV-infected individuals, because they were more likely to
die before experiencing a comorbid disease. We found that uni-
and multivariable associations with age remained unchanged.
DISCUSSION
We prospectively assessed incident non-AIDS comorbidity and
studied the association between age and clinical end points. Over
a 36-month period, 8444 participants were followed up for
22 591 person-years. The rates for death, AIDS-defining diseases,
and any clinical end point were 7.81 deaths per 1000 person-
years (95% CI, 6.74–9.05 deaths per 1000 person-years), 4.32
cases per 1000 person-years (95% CI, 3.53–5.28 cases per
1000 person-years), and 53.3 cases per 1000 person-years (95%
CI, 50.3–56.6 cases per 1000 person-years), respectively. We
observed 994 incident non-AIDS events in the reference period,
and non-AIDS events outnumbered HIV-related events. HRs for
stroke, myocardial infarction, bone fractures with assumed ade-
quate or inadequate trauma, osteoporosis, diabetes mellitus, and
non-AIDS malignancies were higher for age groups 50–64 years
and $65 years, compared with participants ,50 years of age.
After multivariable adjustment for CD4 cell counts, viral load,
sex, former and current injection drug use, former and current
smoking, and duration of HIV infection, associations with age
remained robust.
A comparison of our results with an age-matched HIV-
uninfected population with similar comorbidity or behavior is
difficult, because we had no suitable HIV-uninfected control
group in our country. Also, comparisons with the European
Cancer Observatory [19] or the MONICA Augsburg Cohort
(MAC) , a large cohort of HIV-uninfected persons in Germany
[20, 21], are problematical, because the age distribution is dif-
ferent. Nevertheless, comparison of such data suggest a higher
overall IR of cancer (IR, 3.764 cases per 1000 person-years) in
our cohort of HIV-infected persons and higher IRs of myocar-
dial infarction (IR derived from MAC, 3.51 cases per 1000
person-years; 95% CI, 3.17–3.87 cases per 1000 person-years),
and diabetes mellitus (IR derived fromMAC, 5.32 cases per 1000
person-years; 95% CI, 4.84–5.83 cases per 1000 person-years) in
our SHCS participants aged 50–64 years.
Previous studies compared cross-sectional prevalence [9, 12,
22–26] or IRs [8, 10, 11, 27, 28] of comorbid disease between
HIV-infected and HIV-uninfected individuals. In HIV-infected
individuals, higher rates of bone fractures [9], osteoporosis
[25], pulmonary disease [26], non–AIDS-defining malignancies
[8, 27, 28], and cardiovascular disease [10, 11], were reported.
However, such data deserve careful interpretation, because most
of these studies were population-based, lacked prospective
Figure 2. A, Numbers of different classes of non–human immuno-
deficiency virus (HIV) medication, stratified by age. Classes of non-HIV
medications were antihypertensives, lipid-lowering agents, oral antidiabetics,
insulin, antiplatelet drugs, and antidepressants. B, Numbers of different
non-AIDS comorbidities, stratified by age. Classes of non-AIDS comorbidities
were bacterial pneumonia, cerebral infarction, coronary angioplasty,
myocardial infarction, procedure on other arteries, pulmonary embolism, deep
vein thrombosis, fracture with adequate or inadequate trauma, osteoporosis,
avascular necrosis of bone, diabetes mellitus, pancreatitis, liver-associated
event, kidney-associated event, non-AIDS malignancy, arterial hypertension,
hyperlipdemiemia, depression, active injection drug use, and active hepatitis
B or C.
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capture of end points, often relied on retrospective analysis of
International Classification of Disease diagnosis codes, and did
not control for long-term ART use and other important risks,
such as smoking, alcohol, or substance use. Furthermore, it is
especially important to consider that HIV-infected persons differ
from HIV-uninfected control subjects with respect to metabolic
changes because of long-term toxicity of ART [29–31], with
respect to alcohol consumption, smoking, body mass index,
and rates of HBV or HCV coinfections. This co-occurrence of
multiple diseases or risk factors leads to novel patterns of mul-
timorbidity that substantially differ by HIV status and age [23].
Effects of age and HIV infection on single non-AIDS diseases
were previously reported [8–12, 23]. Comparisons between
HIV-infected and HIV-uninfected persons showed higher
rates of bone fractures [9], acute myocardial infarction [10, 11],
diabetes mellitus [12], and non–AIDS-defining cancers [8, 28]
among older HIV-infected individuals. The Veterans Aging
Cohort Study (VACS) reported that HIV-infected participants
aged$50 years more likely suffered from hypertension, diabetes
mellitus, vascular disease, pulmonary disease, and renal disease,
whereas substance use and psychiatric disorders were less likely
in this age group [23]. The small cross-sectional National Health
and Nutrition Examination Survey found a higher prevalence of
hypertension, hypertriglyceridemia, low bone mineral density,
and lipodystrophy in HIV-infected persons aged $50 years,
compared with matched HIV-uninfected control subjects, and
suggested that HIV accelerates biological aging [24]. However,
the concept of premature aging of HIV-infected persons appears
to be controversial, particularly when considering the investi-
gation on effects of age on non–AIDS-defining malignancies
by Shiels et al [32]. They compared age at diagnosis for different
types of cancer in HIV-infected andHIV-uninfected populations
Table 3. Overall and Age-Related Incidence Rates of Clinical Events, Hospitalizations, and Deaths, From 1 January 2008 Through
31 December 2010
End points
Totala
no. (%)
Rate (95% CI) per
1000 person-years
Rate (95% CI) per 1000 person-years, by age group
P valueb,50 50–64 $65
Non-AIDS Comorbidities 994 (100)
Bacterial pneumonia 201 (20.1) 9.03 (7.87–10.4) 7.54 (6.27–9.05) 12.8 (10.2–16.0) 9.41 (5.21–17.0) .005
Cerebral infarction 39 (3.9) 1.73 (1.26–2.37) 0.784 (0.445–1.38) 2.81 (1.75–4.52) 8.53 (4.59–15.9) ,.001
Coronary angioplasty 76 (7.6) 3.38 (2.70–4.23) 1.31 (0.843–2.02) 7.32 (5.35–9.84) 10.3 (5.84–18.1) ,.001
Myocardial infarction 55 (5.5) 2.44 (1.88–3.18) 0.849 (0.493–1.46) 5.98 (4.31–8.29) 5.08 (2.28–11.3) ,.001
Procedure on other arteries 31 (3.1) 1.37 (0.967–1.95) 0.718 (0.398–1.30) 2.81 (1.75–4.52) 2.54 (0.819–7.87) .001
Pulmonary embolism 16 (1.6) 0.709 (0.434–1.16) 0.522 (0.261–1.04) 0.989 (0.444–2.20) 1.69 (0.423–6.77) .089
Deep vein thrombosis 32 (3.2) 1.42 (1.00–2.00) 1.31 (0.843–2.03) 1.65 (0.888–3.07) 1.69 (0.422–6.74) .539
Fracture, adequate trauma 123 (12.4) 5.48 (4.60–6.54) 3.67 (2.82–4.77) 8.67 (6.61–11.4) 12.8 (7.73–21.3) ,.001
Fracture, inadequate trauma 37 (3.7) 1.64 (1.19–2.26) 0.783 (0.445–1.38) 3.14 (2.00–4.93) 5.08 (2.28–11.3) ,.001
Osteoporosis 61 (6.1) 2.71 (2.11–3.48) 1.50 (0.998–2.26) 4.64 (3.21–6.72) 8.49 (4.57–15.8) ,.001
Avascular necrosis of bone 22 (2.2) 0.974 (0.642–1.48) 0.979 (0.590–1.62) 0.824 (0.342–1.98) 1.69 (0.442–6.75) .783
Diabetes mellitus 70 (7.0) 3.12 (2.46–3.94) 2.09 (1.48–2.96) 4.65 (3.21–6.74) 8.56 (4.61–15.9) ,.001
Pancreatitis 28 (2.8) 1.24 (0.857–1.80) 0.783 (0.445–1.38) 2.31 (1.37–3.90) 1.69 (0.422–6.75) .017
Liver-associated eventc 57 (5.7) 2.53 (1.95–3.28) 2.22 (1.59–3.11) 3.64 (2.40–5.53) 0.843 (0.119–5.9) .538
Kidney-associated eventd 31 (3.1) 1.37 (0.967–1.95) 1.18 (0.741–1.87) 1.65 (0.888–3.07) 2.53 (0.818–7.86) .176
Non–AIDS-defining malignancy 115 (11.6) 5.12 (4.27–6.15) 2.42 (1.75–3.34) 9.66 (7.47–12.5) 17.2 (11.1–26.7) ,.001
HIV-related events 195 (100)
CDC stage B event 100 (51.3) 4.52 (3.72–5.51) 4.95 (3.94–6.22) 3.52 (2.29–5.39) 4.25 (1.77–10.2) .257
CDC stage C event 95 (48.7) 4.32 (3.53–5.28) 3.88 (3.00–5.02) 5.08 (3.55–7.27) 6.05 (2.89–12.7) .134
Hospitalizations 1812 (100)
Somatic disease 1484 (79.9) 74.4 (70.7–78.3) 63.1 (59.0–67.4) 91.5 (83.7–100) 142 (121–168) ,.001
Injury 119 (6.6) 5.30 (4.43–6.35) 4.39 (3.46–5.58) 5.65 (4.04–7.91) 15.4 (9.71–24.4) ,.001
Psychiatric disease 245 (13.5) 11.0 (9.73–12.5) 11.8 (10.3–13.8) 10.0 (7.77–12.9) 5.07 (2.28–11.3) .028
Deaths 177 (100) 7.81 (6.74–9.05) 5.92 (4.82–7.28) 9.68 (7.50–12.5) 22.5 (15.4–33.8) ,.001
Abbreviation: CDC, Centers for Disease Control and Prevention; CI, confidence interval.
a Some observations had to be deleted due to missing covariables.
b Test for trend across age groups.
c Events like nonalcoholic steatosis hepatis (n5 10), diagnosis of liver cirrhosis by histology (n5 15), spontaneous bacterial peritonitis (n5 2), bleeding form gastric
or esophageal varices (n 5 14), diagnosis of portal hypertension (n 5 10), hepatic encephalopathy stage III–IV (n 5 3), and liver transplantation (n 5 3) were
summarized as ‘‘liver-associated events.’’
d Events like kidney biopsy (n 5 21), kidney transplantation (n 5 1) and permanent dialysis (n 5 9) were summarized as ‘‘kidney-associated events.’’
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after adjustment for age differences between groups and con-
cluded that their analyses do not support premature aging as a
cause of cancer in HIV-infected persons.
Residual immunodeficiency and a state of chronic inflam-
mationmay add to risk of age-associated non-AIDS diseases also
among persons taking ART [6]. We observed that individuals
with higher CD4 cell counts were less likely to develop HIV-
associated and non-AIDS events, and they were less likely to
die. A detectable HIV RNA level was associated with the de-
velopment of bacterial pneumonia, new CDC B– and C–defining
events, and certain non-AIDS end points. Patients with lower
CD4 cell counts are known to have a higher mortality [2], but
they also seemed to develop age-related events more frequently
in our analyses. This is in line with results from the VACS, which
showed that low CD4 cell counts and detectable viral loads were
associated with vascular and pulmonary diseases [23].
Strengths of our study include its statistical power, because
of the large number of patient-years, and the prospective
collection of incident events with use of structured event re-
porting forms. Because of the design of the cohort, we were
able to control for many cofactors known to be associated
with HIV progression or occurrence of comorbid events.
Several limitations should also be noted. First, we could not
compare incidences of disease in HIV-infected patients with
those in a demographically similar HIV-uninfected reference
group. This complicates the interpretation of IRs in persons
aged .65 years, leaving questions open, such as whether in-
creased comorbidity simply reflects being older or whether risk
of comorbidity is increased because of reduced immune recovery,
despite HIV control, in persons who are infected at an older age.
Second, although SHCS institutions provide primary care and,
thus, continuously document patients’ history and clinical end
Table 4. Uni- and Multivariable Hazard Ratios for Clinical Events From 1 January 2008 Until 31 December 2010, Stratified by Age
Events
Univariable analyses Multivariable analyses
50–64 HR (95% CI)a $65 HR (95% CI)a P value 50–64 HR (95% CI)a $65 HR (95% CI)a P valued
Non-AIDS comorbidities
Bacterial pneumonia 1.69 (1.27–2.26) 1.25 (0.673–2.32) .002 1.89 (1.40–2.55) 2.04 (1.08–3.88) ,.001
Cerebral infarction 3.59 (1.72–7.52) 10.9 (4.70–25.2) ,.001 3.96 (1.86–8.42) 17.7 (7.06–44.5) ,.001
Coronary angioplasty 5.60 (3.30–9.50) 7.86 (3.84–16.1) ,.001 4.72 (2.76–8.10) 7.43 (3.51–15.7) ,.001
Myocardial infarction 7.05 (3.74–13.3) 5.99 (2.27–15.7) ,.001 5.95 (3.12–11.3) 5.89 (2.17–16.0) ,.001
Procedure on other arteries 3.92 (1.83–8.36) 3.53 (0.987–12.7) .001 4.29 (1.97–9.36) 5.04 (1.34–19.1) ,.001
Pulmonary embolism 1.90 (0.660–5.48) 3.25 (0.691–15.3) .272 1.87 (0.632–5.52) 3.93 (0.760–20.4) .251
Deep vein thrombosis 1.26 (0.590–2.68) 1.29 (0.302–5.52) .815 1.29 (0.594–2.80) 2.06 (0.453–9.40) .608
Fracture, adequate trauma 2.37 (1.63–3.46) 3.52 (1.99–6.23) ,.001 2.28 (1.55–3.36) 4.71 (2.57–8.63) ,.001
Fracture, inadequate trauma 4.01 (1.95–8.25) 6.46 (2.42–17.2) ,.001 3.93 (1.88–8.24) 10.5 (3.58–30.5) ,.001
Osteoporosis 3.09 (1.78–5.36) 5.65 (2.69–11.9) ,.001 3.60 (2.04–6.34) 9.13 (4.10–20.3) ,.001
Avascular necrosis of bone 0.838 (0.305–2.30) 1.72 (0.393–7.51) .720 0.767 (0.274–2.15) 2.32 (0.489–11.0) .493
Diabetes mellitus 2.23 (1.34–3.70) 4.09 (2.01–8.31) ,.001 2.23 (1.33–3.76) 3.75 (1.80–7.85) ,.001
Pancreatitis 2.94 (1.36–6.36) 2.15 (0.481–9.61) .023 3.27 (1.48–7.24) 3.85 (0.799–18.5) .01
Liver-associated eventb 1.64 (0.959–2.80) 0.379 (0.519–2.77) .082 1.29 (0.748–2.23) 0.494 (0.066–3.72) .440
Kidney-associated eventc 1.40 (0.647–3.04) 2.16 (0.637–7.34) .426 1.41 (0.638–3.14) 2.84 (0.781–10.3) .303
Non-AIDS malignancy 3.98 (2.64–6.02) 7.11 (4.13–12.3) ,.001 3.73 (2.45–5.69) 6.88 (3.89–12.2) ,.001
HIV-related events
CDC stage B event 0.771 (0.438–1.15) 0.860 (0.348–2.13) .361 1.00 (0.616–1.66) 1.18 (0.468–2.95) .945
CDC stage C event 1.31 (0.842–2.03) 1.56 (0.714–3.42) .341 1.56 (0.990–2.44) 1.84 (0.826–4.12) .100
Hospitalizations
Somatic disease 1.45 (1.30–1.62) 2.27 (1.89–2.71) ,.001 1.59 (1.42–1.78) 2.88 (2.39–3.48) ,.001
Injury 1.28 (0.851–1.94) 3.50 (2.08–5.88) ,.001 1.35 (0.882–2.06) 4.82 (2.75–8.44) ,.001
Psychiatric disease 0.841 (0.628–1.13) 0.423 (0.189–0.963) .042 0.976 (0.724–1.32) 0.867 (0.379–1.99) .936
Death 1.63 (1.17–2.26) 3.80 (2.47–5.84) ,.001 1.67 (1.19–2.33) 6.25 (3.90–10.0) ,.001
Multivariable models were adjusted for latest square-root–transformed CD4, female sex, former injecting drug use, never injecting drug use, former smoking, never
smoking, latest log10-transformed HIV-RNA copies/mL and years of HIV infection.
Abbreviations: HR, hazard ratio; CI, confidence interval; HIV, human immunodeficiency virus.
a Participants ,50 years old formed the reference group.
b Events like nonalcoholic steatosis hepatis, diagnosis of liver cirrhosis by histology, spontaneous bacterial peritonitis, bleeding form gastric or esophageal varices,
diagnosis of portal hypertension, hepatic encephalopathy stage III–IV, and liver transplantation were summarized as ‘‘liver-associated events.’’
c Events like kidney biopsy, kidney transplantation and permanent dialysis were summarized as ‘‘kidney-associated events.’’
d Likelihood ratio test for global P value of age.
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points, it cannot completely be excluded that participants at-
tended other institutions for care and that such information
was not reported by participants or care providers. There is no
formal record linkage with other hospitals. Third, outcome is
particularly different in injection drug users, because they more
often suffer from liver-related comorbidities or smoking-
related complications, are less likely to participate in a cohort
study, and are underrepresented in older age groups. However,
we considered such differences of participants’ characteristics
and behavior by adjusting the multivariable models also for
former versus current injection drug use and former versus
current smoking.
In conclusion, non-AIDS comorbidities, particularly car-
diovascular disease, osteoporosis, diabetes mellitus, and non–
AIDS-defining malignancies, become increasingly important
in HIV-infected persons and increase with older age. In addition
to disease-specific research, studies on comprehensive HIV care
need to focus on patterns of consecutive comorbidity and con-
current multimorbidity. Because age is a nonmodifiable factor, it
is particularly important to carefully screen for and prevent age-
related modifiable risks of non-AIDS comorbidity.
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